Trimazosin: Difference between revisions
m Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +) |
No edit summary |
||
Line 1: | Line 1: | ||
{{Drugbox | {{Drugbox | ||
| | | Verifiedfields = changed | ||
| | | Watchedfields = changed | ||
| | | verifiedrevid = 448137147 | ||
| | | IUPAC_name = (2-hydroxy-2-methylpropyl) 4-(4-amino-6,7,8-trimethoxyquinazolin-2-yl)piperazine-1-carboxylate | ||
| | | image = Trimazosin.png | ||
<!--Clinical data--> | |||
| tradename = | |||
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> | |||
| pregnancy_US = <!-- A / B / C / D / X --> | |||
| pregnancy_category = | |||
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--> | |||
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII --> | |||
| | | legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C --> | ||
| pregnancy_AU | | legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> | ||
| pregnancy_US | | legal_status = | ||
| pregnancy_category= | | routes_of_administration = | ||
| legal_AU = | |||
| legal_CA = | <!--Pharmacokinetic data--> | ||
| legal_UK = | | bioavailability = | ||
| legal_US = | | protein_bound = | ||
| legal_status = | | metabolism = | ||
| | | elimination_half-life = | ||
| excretion = | |||
<!--Identifiers--> | |||
| CAS_number_Ref = {{cascite|correct|??}} | |||
| CAS_number = 53746-46-6 | |||
| ATC_prefix = C02 | |||
| ATC_suffix = CA03 | |||
| PubChem = 37264 | |||
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} | |||
| DrugBank = | |||
| UNII_Ref = {{fdacite|correct|FDA}} | |||
| UNII = 31L760807H | |||
| ChEMBL_Ref = {{ebicite|changed|EBI}} | |||
| ChEMBL = 513301 | |||
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} | |||
| ChemSpiderID = 34203 | |||
| smiles = O=C(OCC(O)(C)C)N3CCN(c1nc(N)c2c(n1)c(OC)c(OC)c(OC)c2)CC3 | |||
| InChI = 1/C20H29N5O6/c1-20(2,27)11-31-19(26)25-8-6-24(7-9-25)18-22-14-12(17(21)23-18)10-13(28-3)15(29-4)16(14)30-5/h10,27H,6-9,11H2,1-5H3,(H2,21,22,23) | |||
| InChIKey = YNZXWQJZEDLQEG-UHFFFAOYAG | |||
| StdInChI_Ref = {{stdinchicite|changed|chemspider}} | |||
| StdInChI = 1S/C20H29N5O6/c1-20(2,27)11-31-19(26)25-8-6-24(7-9-25)18-22-14-12(17(21)23-18)10-13(28-3)15(29-4)16(14)30-5/h10,27H,6-9,11H2,1-5H3,(H2,21,22,23) | |||
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}} | |||
| StdInChIKey = YNZXWQJZEDLQEG-UHFFFAOYSA-N | |||
<!--Chemical data--> | |||
| C=20 | H=29 | N=5 | O=6 | |||
| molecular_weight = 435.47 g/mol | |||
}} | }} | ||
{{CMG}} | __NOTOC__ | ||
{{SI}} | |||
{{CMG}}; {{AE}} {{KS}} | |||
==Overview== | |||
'''Trimazosin''' is a [[sympatholytic]] drug. | |||
It is an [[alpha blocker]].<ref name="pmid3780829">{{cite journal |author=van Kalken CK, van der Meulen J, Oe PL, Vriesendorp R, Donker AJ |title=Pharmacokinetics of trimazosin and its effects on blood pressure, renal function and proteinuria during short-term therapy of patients with impaired renal function and hypertension |journal=Eur. J. Clin. Pharmacol. |volume=31 |issue=1 |pages=63–8 |year=1986 |pmid=3780829 |doi= 10.1007/BF00870988|url=}}</ref> | |||
[[File:Trimazocin.png|500px]] | |||
Hess, H. J.; 1972. | |||
==References== | |||
{{reflist}} | |||
{{Antihypertensives and diuretics}} | {{Antihypertensives and diuretics}} | ||
[[Category:Drugs]] | [[Category:Antihypertensive agents]] | ||
[[Category:Cardiovascular Drugs]] | |||
[[Category:Drug]] |
Revision as of 17:12, 23 July 2014
Clinical data | |
---|---|
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C20H29N5O6 |
Molar mass | 435.47 g/mol |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
WikiDoc Resources for Trimazosin |
Articles |
---|
Most recent articles on Trimazosin |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Trimazosin at Clinical Trials.gov Clinical Trials on Trimazosin at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Trimazosin
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Trimazosin Discussion groups on Trimazosin Patient Handouts on Trimazosin Directions to Hospitals Treating Trimazosin Risk calculators and risk factors for Trimazosin
|
Healthcare Provider Resources |
Causes & Risk Factors for Trimazosin |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Kiran Singh, M.D. [2]
Overview
Trimazosin is a sympatholytic drug.
It is an alpha blocker.[1]
Hess, H. J.; 1972.
References
- ↑ van Kalken CK, van der Meulen J, Oe PL, Vriesendorp R, Donker AJ (1986). "Pharmacokinetics of trimazosin and its effects on blood pressure, renal function and proteinuria during short-term therapy of patients with impaired renal function and hypertension". Eur. J. Clin. Pharmacol. 31 (1): 63–8. doi:10.1007/BF00870988. PMID 3780829.
- Pages with script errors
- CS1 maint: Multiple names: authors list
- Articles with changed ChemSpider identifier
- Articles with changed EBI identifier
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles with changed InChI identifier
- Chemical articles with unknown parameter in Infobox drug
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Drugs with no legal status
- Drugboxes which contain changes to verified fields
- Drugboxes which contain changes to watched fields
- Antihypertensive agents
- Cardiovascular Drugs
- Drug